Loading…

Willingness to Pay for a Reduction in Mortality Risk after a Myocardial Infarction: An Application of the Contingent Valuation Method to the Case of Eplerenone

In order to allocate health care resources more efficiently, it is necessary to relate health improvements provided by new medicines to their cost. It is necessary to ascertain when the additional cost of introducing a new health technology is justified by the additional health gain produced. Eplere...

Full description

Saved in:
Bibliographic Details
Published in:The European journal of health economics 2008-02, Vol.9 (1), p.69-78
Main Authors: Pinto-Prades, Jose-Luis, Farreras, Veronica, de Bobadilla, Jaime Fernandez
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c492t-8f5ceb553f2de0d81e30f2e0c321b6cbb0130d55210d5dec50da9f9f1a6b4f53
cites cdi_FETCH-LOGICAL-c492t-8f5ceb553f2de0d81e30f2e0c321b6cbb0130d55210d5dec50da9f9f1a6b4f53
container_end_page 78
container_issue 1
container_start_page 69
container_title The European journal of health economics
container_volume 9
creator Pinto-Prades, Jose-Luis
Farreras, Veronica
de Bobadilla, Jaime Fernandez
description In order to allocate health care resources more efficiently, it is necessary to relate health improvements provided by new medicines to their cost. It is necessary to ascertain when the additional cost of introducing a new health technology is justified by the additional health gain produced. Eplerenone is a new medicine that reduces the risk of death after myocardial infarction (MI) but produces additional cost to the health system. The contingent valuation approach can be used to measure the monetary value of this risk reduction and to estimate society's willingness to pay (WTP) for a new medicine that reduces the risk of death after MI by 2% points. We used a contingent valuation approach to evaluate WTP amongst members of the general population. We used the ex-ante and the ex-post approach. In the ex-ante approach, subjects are asked if they would accept an increase in their taxes in order to have access to eplerenone should they need it in the future. In the ex-post approach, subjects are asked if they would pay a certain amount of money as copayment per month during 5 years if they suffered an MI. We used the dichotomous choice method, using five bids in each approach. The WTP was estimated using both single-bound and double-bound dichotomous choice (SBDC, DBDC). Extensive piloting ( n = 187) preceded the final survey (n = 350). The WTP in the ex-ante case was €58 per year under both SBDC and DBDC. In the ex-post case, monthly WTP was €141 for the SBDC and €85 for the DBDC. Subjects with higher income and subjects with a higher perception of risk showed a higher WTP (P
doi_str_mv 10.1007/s10198-007-0041-x
format article
fullrecord <record><control><sourceid>jstor_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_70204601</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>40283698</jstor_id><sourcerecordid>40283698</sourcerecordid><originalsourceid>FETCH-LOGICAL-c492t-8f5ceb553f2de0d81e30f2e0c321b6cbb0130d55210d5dec50da9f9f1a6b4f53</originalsourceid><addsrcrecordid>eNp9kc1u1DAUhSMEon88AAuQV-wCthPnh91oVGiljqiqCpaWY19TDx472I7UeZq-Ks5kKDsWtq90v3OufE9RvCX4I8G4_RQJJn1X5jKfmpSPL4pT0pCubBtMXv6tWd-dFGcxbjGmtKXV6-KEtHXd4p6dFk8_jLXG_XQQI0oe3Yo90j4gge5ATTIZ75BxaONDEtakPboz8RcSOsHMbPZeiqCMsOjaaREO_Ge0cmg1jtZIcdB7jdIDoLV3KU8Cl9B3Yaelt4H04NU8-YCICDN-OVoI4LyDi-KVFjbCm-N7Xtx_ubxfX5U3375er1c3pax7mspOMwkDY5WmCrDqCFRYU8CyomRo5DBgUmHFGCX5ViAZVqLXvSaiGWrNqvPiw2I7Bv97gpj4zkQJ1goHfoq8xRTXeakZJAsog48xgOZjMDsR9pxgPofCl1D4XM6h8MeseX80n4YdqH-KYwoZoAsQcytvKPCtn4LL__2v67tFtI3Jh2fTGtOuavqu-gNDMKRH</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>70204601</pqid></control><display><type>article</type><title>Willingness to Pay for a Reduction in Mortality Risk after a Myocardial Infarction: An Application of the Contingent Valuation Method to the Case of Eplerenone</title><source>JSTOR Archival Journals and Primary Sources Collection</source><source>ABI/INFORM Global</source><source>EconLit with Full Text【Remote access available】</source><source>Springer Link</source><creator>Pinto-Prades, Jose-Luis ; Farreras, Veronica ; de Bobadilla, Jaime Fernandez</creator><creatorcontrib>Pinto-Prades, Jose-Luis ; Farreras, Veronica ; de Bobadilla, Jaime Fernandez</creatorcontrib><description>In order to allocate health care resources more efficiently, it is necessary to relate health improvements provided by new medicines to their cost. It is necessary to ascertain when the additional cost of introducing a new health technology is justified by the additional health gain produced. Eplerenone is a new medicine that reduces the risk of death after myocardial infarction (MI) but produces additional cost to the health system. The contingent valuation approach can be used to measure the monetary value of this risk reduction and to estimate society's willingness to pay (WTP) for a new medicine that reduces the risk of death after MI by 2% points. We used a contingent valuation approach to evaluate WTP amongst members of the general population. We used the ex-ante and the ex-post approach. In the ex-ante approach, subjects are asked if they would accept an increase in their taxes in order to have access to eplerenone should they need it in the future. In the ex-post approach, subjects are asked if they would pay a certain amount of money as copayment per month during 5 years if they suffered an MI. We used the dichotomous choice method, using five bids in each approach. The WTP was estimated using both single-bound and double-bound dichotomous choice (SBDC, DBDC). Extensive piloting ( n = 187) preceded the final survey (n = 350). The WTP in the ex-ante case was €58 per year under both SBDC and DBDC. In the ex-post case, monthly WTP was €141 for the SBDC and €85 for the DBDC. Subjects with higher income and subjects with a higher perception of risk showed a higher WTP (P&lt;0.05). Society is willing to pay an additional amount of money in order to give eplerenone to present and future patients. We estimate that €85 per month is a conservative estimate of the monetary value of a 2% risk reduction in mortality after MI and to spend this additional amount of money in Eplerenone can be considered an efficient policy.</description><identifier>ISSN: 1618-7598</identifier><identifier>EISSN: 1618-7601</identifier><identifier>DOI: 10.1007/s10198-007-0041-x</identifier><identifier>PMID: 17447095</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer</publisher><subject>Allocative efficiency ; Attitude to Health ; Cost efficiency ; Cost-Benefit Analysis ; Death ; Economic Policy ; Estimated taxes ; Estimation methods ; Female ; Financial risk ; Financing, Personal - economics ; Focus Groups ; Health Care Management ; Health Care Surveys ; Health Economics ; Humans ; Income taxes ; Male ; Medical technology ; Medicine ; Medicine &amp; Public Health ; Middle Aged ; Mineralocorticoid Receptor Antagonists - economics ; Mineralocorticoid Receptor Antagonists - therapeutic use ; Mortality ; Myocardial infarction ; Myocardial Infarction - mortality ; Original Paper ; Pharmacoeconomics and Health Outcomes ; Public Finance ; Public Health ; Risk Reduction Behavior ; Spain ; Spironolactone - analogs &amp; derivatives ; Spironolactone - economics ; Spironolactone - therapeutic use</subject><ispartof>The European journal of health economics, 2008-02, Vol.9 (1), p.69-78</ispartof><rights>Copyright 2008 Springer-Verlag Berlin Heidelberg</rights><rights>Springer-Verlag 2007</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c492t-8f5ceb553f2de0d81e30f2e0c321b6cbb0130d55210d5dec50da9f9f1a6b4f53</citedby><cites>FETCH-LOGICAL-c492t-8f5ceb553f2de0d81e30f2e0c321b6cbb0130d55210d5dec50da9f9f1a6b4f53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/40283698$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/40283698$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,36061,58238,58471</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17447095$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pinto-Prades, Jose-Luis</creatorcontrib><creatorcontrib>Farreras, Veronica</creatorcontrib><creatorcontrib>de Bobadilla, Jaime Fernandez</creatorcontrib><title>Willingness to Pay for a Reduction in Mortality Risk after a Myocardial Infarction: An Application of the Contingent Valuation Method to the Case of Eplerenone</title><title>The European journal of health economics</title><addtitle>Eur J Health Econ</addtitle><addtitle>Eur J Health Econ</addtitle><description>In order to allocate health care resources more efficiently, it is necessary to relate health improvements provided by new medicines to their cost. It is necessary to ascertain when the additional cost of introducing a new health technology is justified by the additional health gain produced. Eplerenone is a new medicine that reduces the risk of death after myocardial infarction (MI) but produces additional cost to the health system. The contingent valuation approach can be used to measure the monetary value of this risk reduction and to estimate society's willingness to pay (WTP) for a new medicine that reduces the risk of death after MI by 2% points. We used a contingent valuation approach to evaluate WTP amongst members of the general population. We used the ex-ante and the ex-post approach. In the ex-ante approach, subjects are asked if they would accept an increase in their taxes in order to have access to eplerenone should they need it in the future. In the ex-post approach, subjects are asked if they would pay a certain amount of money as copayment per month during 5 years if they suffered an MI. We used the dichotomous choice method, using five bids in each approach. The WTP was estimated using both single-bound and double-bound dichotomous choice (SBDC, DBDC). Extensive piloting ( n = 187) preceded the final survey (n = 350). The WTP in the ex-ante case was €58 per year under both SBDC and DBDC. In the ex-post case, monthly WTP was €141 for the SBDC and €85 for the DBDC. Subjects with higher income and subjects with a higher perception of risk showed a higher WTP (P&lt;0.05). Society is willing to pay an additional amount of money in order to give eplerenone to present and future patients. We estimate that €85 per month is a conservative estimate of the monetary value of a 2% risk reduction in mortality after MI and to spend this additional amount of money in Eplerenone can be considered an efficient policy.</description><subject>Allocative efficiency</subject><subject>Attitude to Health</subject><subject>Cost efficiency</subject><subject>Cost-Benefit Analysis</subject><subject>Death</subject><subject>Economic Policy</subject><subject>Estimated taxes</subject><subject>Estimation methods</subject><subject>Female</subject><subject>Financial risk</subject><subject>Financing, Personal - economics</subject><subject>Focus Groups</subject><subject>Health Care Management</subject><subject>Health Care Surveys</subject><subject>Health Economics</subject><subject>Humans</subject><subject>Income taxes</subject><subject>Male</subject><subject>Medical technology</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Middle Aged</subject><subject>Mineralocorticoid Receptor Antagonists - economics</subject><subject>Mineralocorticoid Receptor Antagonists - therapeutic use</subject><subject>Mortality</subject><subject>Myocardial infarction</subject><subject>Myocardial Infarction - mortality</subject><subject>Original Paper</subject><subject>Pharmacoeconomics and Health Outcomes</subject><subject>Public Finance</subject><subject>Public Health</subject><subject>Risk Reduction Behavior</subject><subject>Spain</subject><subject>Spironolactone - analogs &amp; derivatives</subject><subject>Spironolactone - economics</subject><subject>Spironolactone - therapeutic use</subject><issn>1618-7598</issn><issn>1618-7601</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><recordid>eNp9kc1u1DAUhSMEon88AAuQV-wCthPnh91oVGiljqiqCpaWY19TDx472I7UeZq-Ks5kKDsWtq90v3OufE9RvCX4I8G4_RQJJn1X5jKfmpSPL4pT0pCubBtMXv6tWd-dFGcxbjGmtKXV6-KEtHXd4p6dFk8_jLXG_XQQI0oe3Yo90j4gge5ATTIZ75BxaONDEtakPboz8RcSOsHMbPZeiqCMsOjaaREO_Ge0cmg1jtZIcdB7jdIDoLV3KU8Cl9B3Yaelt4H04NU8-YCICDN-OVoI4LyDi-KVFjbCm-N7Xtx_ubxfX5U3375er1c3pax7mspOMwkDY5WmCrDqCFRYU8CyomRo5DBgUmHFGCX5ViAZVqLXvSaiGWrNqvPiw2I7Bv97gpj4zkQJ1goHfoq8xRTXeakZJAsog48xgOZjMDsR9pxgPofCl1D4XM6h8MeseX80n4YdqH-KYwoZoAsQcytvKPCtn4LL__2v67tFtI3Jh2fTGtOuavqu-gNDMKRH</recordid><startdate>20080201</startdate><enddate>20080201</enddate><creator>Pinto-Prades, Jose-Luis</creator><creator>Farreras, Veronica</creator><creator>de Bobadilla, Jaime Fernandez</creator><general>Springer</general><general>Springer-Verlag</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20080201</creationdate><title>Willingness to Pay for a Reduction in Mortality Risk after a Myocardial Infarction: An Application of the Contingent Valuation Method to the Case of Eplerenone</title><author>Pinto-Prades, Jose-Luis ; Farreras, Veronica ; de Bobadilla, Jaime Fernandez</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c492t-8f5ceb553f2de0d81e30f2e0c321b6cbb0130d55210d5dec50da9f9f1a6b4f53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Allocative efficiency</topic><topic>Attitude to Health</topic><topic>Cost efficiency</topic><topic>Cost-Benefit Analysis</topic><topic>Death</topic><topic>Economic Policy</topic><topic>Estimated taxes</topic><topic>Estimation methods</topic><topic>Female</topic><topic>Financial risk</topic><topic>Financing, Personal - economics</topic><topic>Focus Groups</topic><topic>Health Care Management</topic><topic>Health Care Surveys</topic><topic>Health Economics</topic><topic>Humans</topic><topic>Income taxes</topic><topic>Male</topic><topic>Medical technology</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Middle Aged</topic><topic>Mineralocorticoid Receptor Antagonists - economics</topic><topic>Mineralocorticoid Receptor Antagonists - therapeutic use</topic><topic>Mortality</topic><topic>Myocardial infarction</topic><topic>Myocardial Infarction - mortality</topic><topic>Original Paper</topic><topic>Pharmacoeconomics and Health Outcomes</topic><topic>Public Finance</topic><topic>Public Health</topic><topic>Risk Reduction Behavior</topic><topic>Spain</topic><topic>Spironolactone - analogs &amp; derivatives</topic><topic>Spironolactone - economics</topic><topic>Spironolactone - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pinto-Prades, Jose-Luis</creatorcontrib><creatorcontrib>Farreras, Veronica</creatorcontrib><creatorcontrib>de Bobadilla, Jaime Fernandez</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The European journal of health economics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pinto-Prades, Jose-Luis</au><au>Farreras, Veronica</au><au>de Bobadilla, Jaime Fernandez</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Willingness to Pay for a Reduction in Mortality Risk after a Myocardial Infarction: An Application of the Contingent Valuation Method to the Case of Eplerenone</atitle><jtitle>The European journal of health economics</jtitle><stitle>Eur J Health Econ</stitle><addtitle>Eur J Health Econ</addtitle><date>2008-02-01</date><risdate>2008</risdate><volume>9</volume><issue>1</issue><spage>69</spage><epage>78</epage><pages>69-78</pages><issn>1618-7598</issn><eissn>1618-7601</eissn><abstract>In order to allocate health care resources more efficiently, it is necessary to relate health improvements provided by new medicines to their cost. It is necessary to ascertain when the additional cost of introducing a new health technology is justified by the additional health gain produced. Eplerenone is a new medicine that reduces the risk of death after myocardial infarction (MI) but produces additional cost to the health system. The contingent valuation approach can be used to measure the monetary value of this risk reduction and to estimate society's willingness to pay (WTP) for a new medicine that reduces the risk of death after MI by 2% points. We used a contingent valuation approach to evaluate WTP amongst members of the general population. We used the ex-ante and the ex-post approach. In the ex-ante approach, subjects are asked if they would accept an increase in their taxes in order to have access to eplerenone should they need it in the future. In the ex-post approach, subjects are asked if they would pay a certain amount of money as copayment per month during 5 years if they suffered an MI. We used the dichotomous choice method, using five bids in each approach. The WTP was estimated using both single-bound and double-bound dichotomous choice (SBDC, DBDC). Extensive piloting ( n = 187) preceded the final survey (n = 350). The WTP in the ex-ante case was €58 per year under both SBDC and DBDC. In the ex-post case, monthly WTP was €141 for the SBDC and €85 for the DBDC. Subjects with higher income and subjects with a higher perception of risk showed a higher WTP (P&lt;0.05). Society is willing to pay an additional amount of money in order to give eplerenone to present and future patients. We estimate that €85 per month is a conservative estimate of the monetary value of a 2% risk reduction in mortality after MI and to spend this additional amount of money in Eplerenone can be considered an efficient policy.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer</pub><pmid>17447095</pmid><doi>10.1007/s10198-007-0041-x</doi><tpages>10</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1618-7598
ispartof The European journal of health economics, 2008-02, Vol.9 (1), p.69-78
issn 1618-7598
1618-7601
language eng
recordid cdi_proquest_miscellaneous_70204601
source JSTOR Archival Journals and Primary Sources Collection; ABI/INFORM Global; EconLit with Full Text【Remote access available】; Springer Link
subjects Allocative efficiency
Attitude to Health
Cost efficiency
Cost-Benefit Analysis
Death
Economic Policy
Estimated taxes
Estimation methods
Female
Financial risk
Financing, Personal - economics
Focus Groups
Health Care Management
Health Care Surveys
Health Economics
Humans
Income taxes
Male
Medical technology
Medicine
Medicine & Public Health
Middle Aged
Mineralocorticoid Receptor Antagonists - economics
Mineralocorticoid Receptor Antagonists - therapeutic use
Mortality
Myocardial infarction
Myocardial Infarction - mortality
Original Paper
Pharmacoeconomics and Health Outcomes
Public Finance
Public Health
Risk Reduction Behavior
Spain
Spironolactone - analogs & derivatives
Spironolactone - economics
Spironolactone - therapeutic use
title Willingness to Pay for a Reduction in Mortality Risk after a Myocardial Infarction: An Application of the Contingent Valuation Method to the Case of Eplerenone
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T23%3A17%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Willingness%20to%20Pay%20for%20a%20Reduction%20in%20Mortality%20Risk%20after%20a%20Myocardial%20Infarction:%20An%20Application%20of%20the%20Contingent%20Valuation%20Method%20to%20the%20Case%20of%20Eplerenone&rft.jtitle=The%20European%20journal%20of%20health%20economics&rft.au=Pinto-Prades,%20Jose-Luis&rft.date=2008-02-01&rft.volume=9&rft.issue=1&rft.spage=69&rft.epage=78&rft.pages=69-78&rft.issn=1618-7598&rft.eissn=1618-7601&rft_id=info:doi/10.1007/s10198-007-0041-x&rft_dat=%3Cjstor_proqu%3E40283698%3C/jstor_proqu%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c492t-8f5ceb553f2de0d81e30f2e0c321b6cbb0130d55210d5dec50da9f9f1a6b4f53%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=70204601&rft_id=info:pmid/17447095&rft_jstor_id=40283698&rfr_iscdi=true